Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer

Launched by HELSE NORD-TRØNDELAG HF · Mar 6, 2024

Keywords

ClinConnect Summary

The CoLiQ trial is a study looking at a new way to detect and understand colorectal cancer using a simple blood test. Researchers want to see if they can identify patients with colorectal cancer by checking for specific markers in their blood, known as circulating tumor DNA (ctDNA). The study aims to answer two main questions: first, can these ctDNA markers help spot colorectal cancer patients among those coming in for a colonoscopy? Second, how do these markers change based on the type and progression of the cancer?

To participate in this study, you need to be at least 18 years old and scheduled for a colonoscopy, and you must be able to understand and sign a consent form. If you join the study, you’ll fill out a questionnaire and provide a blood sample. For those already diagnosed with colorectal cancer, an additional blood sample will be collected during routine follow-up visits. This trial is not yet recruiting participants, but it represents an important step in finding easier ways to diagnose and monitor colorectal cancer, which could ultimately lead to better, more personalized treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient ≥ 18 years old summoned for colonoscopy
• • Patient able to understand and sign written informed consent
• Exclusion Criteria:
• • Patient \< 18 years old
• • Patient unable to understand or give written informed consent
• • Patient unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the investigator as unlikely to complete the study